British Journal of Cancer

• 

  Publication Venue For

  • Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer..  119:1451-1455. 2018
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma..  119:663-669. 2018
  • A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features..  119:508-516. 2018
  • Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''..  119:260-262. 2018
  • Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis..  118:1337-1348. 2018
  • A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours..  118:1035-1041. 2018
  • Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study..  118:1123-1129. 2018
  • Influence of obesity-related risk factors in the aetiology of glioma..  118:1020-1027. 2018
  • Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)..  118:648-653. 2018
  • Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up..  117:1723-1731. 2017
  • History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report..  117:1063-1069. 2017
  • Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study..  117:290-299. 2017
  • Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium..  116:1223-1228. 2017
  • Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci..  116:524-535. 2017
  • Dairy, calcium, vitamin D and ovarian cancer risk in African-American women..  115:1122-1130. 2016
  • Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium..  115:95-101. 2016
  • Analgesic medication use and risk of epithelial ovarian cancer in African American women..  114:819-825. 2016
  • A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer..  113:1421-1426. 2015
  • Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium..  113:817-826. 2015
  • Best supportive care in clinical trials: review of the inconsistency in control arm design..  113:6-11. 2015
  • Effect of aerobic training on the host systemic milieu in patients with solid tumours: An exploratory correlative study.  112:825-831. 2015
  • Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial..  110:2427-2433. 2014
  • Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer..  107:1783-1790. 2012
  • Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients..  107:1481-1487. 2012
  • Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours..  107:1399-1408. 2012
  • Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer..  107:482-490. 2012
  • The DNA damage response in viral-induced cellular transformation..  106:429-435. 2012
  • Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer..  105:9-12. 2011
  • Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma..  105:112-117. 2011
  • End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age..  105:28-37. 2011
  • Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration..  104:1575-1586. 2011
  • Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumour)..  104:1452-1458. 2011
  • Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study..  104:413-418. 2011
  • The need for a re-evaluation of best supportive care studies reported to date..  104:390-391. 2011
  • Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor..  103:1554-1561. 2010
  • Guidelines for the welfare and use of animals in cancer research..  102:1555-1577. 2010
  • What is a reasonable cost to refute a preposterous hypothesis?.  102:627-628. 2010
  • Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes..  102:301-315. 2010
  • Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine..  102:144-150. 2010
  • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody..  102:124-133. 2010
  • Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families..  101:2043-2047. 2009
  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study..  101:1986-1994. 2009
  • Erratum: Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium (British Journal of Cancer (2009) 100 (412-420) DOI: 10.1038/sj.bjc.6604820 www.bjcancer.com).  101:1805. 2009
  • Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis..  101:1461-1468. 2009
  • Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening..  101:882-896. 2009
  • MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition..  101:269-277. 2009
  • In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs (British Journal of Cancer (2008) 99, (294-304) DOI: 10.1038/sj.bjc.6604459).  100:1012. 2009
  • Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium..  100:412-420. 2009
  • Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.  100:412-420. 2009
  • A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer..  99:722-726. 2008
  • In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs..  99:294-304. 2008
  • Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis..  98:282-288. 2008
  • Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis..  98:294-299. 2008
  • Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts..  97:735-740. 2007
  • Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy..  97:391-397. 2007
  • Regulation of mammalian horizontal gene transfer by apoptotic DNA fragmentation..  95:1696-1700. 2006
  • Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation..  95:1013-1019. 2006
  • HIF-1 and tumour radiosensitivity..  95:1-5. 2006
  • Birth weight and breast cancer risk..  94:1734-1737. 2006
  • Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis..  93:1350-1355. 2005
  • Array comparative genomic hybridisation (aCGH) analysis of premenopausal breast cancers from a nuclear fallout area and matched cases from Western New York..  93:699-708. 2005
  • Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer..  93:195-199. 2005
  • Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery..  92:1414-1420. 2005
  • Targeted radiotherapy of brain tumours..  90:1469-1473. 2004
  • Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci..  90:510-514. 2004
  • Surrogate markers in antiangiogenesis clinical trials..  89:8-14. 2003
  • Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk..  88:58-62. 2003
  • Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix..  86:274-281. 2002
  • Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour)..  85:98-101. 2001
  • Transfection of the sodium iodide symporter gene for tumour targeting with radioiodine and [At-211]radioastatine.  85:24-24. 2001
  • A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse..  83:588-593. 2000
  • Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer..  83:324-328. 2000
  • Vascular permeability in a human tumour xenograft: molecular charge dependence..  82:1513-1518. 2000
  • Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features..  82:1191-1197. 2000
  • Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells..  82:691-701. 2000
  • Inhibition of growth of OV-1063 human epithelial ovarian cancers and c-jun and c-fos oncogene expression by bombesin antagonists.  83:906-913. 2000
  • Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522..  81:1274-1279. 1999
  • Laminin mediates tethering and spreading of colon cancer cells in physiological shear flow..  80:1927-1934. 1999
  • Bcl10 is not a target for frequent mutation in human carcinomas..  80:1575-1576. 1999
  • G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder..  80:1175-1184. 1999
  • Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia..  79:1717-1722. 1999
  • Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity..  80:87-95. 1999
  • The effects of hyperoxic and hypercarbic gases on tumour blood flow..  80:117-126. 1999
  • Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.  81:966-971. 1999
  • Progesterone receptor gene polymorphism and risk for breast and ovarian cancer..  78:277. 1998
  • Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions..  77:2061-2068. 1998
  • Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia..  77:753-759. 1998
  • Combretastatin A-4 P as a tumour vascular targeting agent.  78:48-48. 1998
  • Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis..  77:51-56. 1998
  • 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.  76:226-233. 1997
  • 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells..  76:226-233. 1997
  • Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma..  76:429-437. 1997
  • Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity..  73:1171-1177. 1996
  • Arteriolar oxygenation in tumour and subcutaneous arterioles: Effects of inspired air oxygen content.  74. 1996
  • Fluorescence ratio imaging of interstitial pH in solid tumours: Effect of glucose on spatial and temporal gradients.  74:1206-1215. 1996
  • The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation..  72:1120-1124. 1995
  • New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment..  72:250. 1995
  • Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma..  71:1181-1187. 1995
  • Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma..  71:1169-1174. 1995
  • Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma.  71:1169-1174. 1995
  • Differences in leucocyte-endothelium interactions between normal and adenocarcinoma bearing tissues in response to radiation..  69:883-889. 1994
  • The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment..  67:734-741. 1993
  • 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation..  67:209-215. 1993
  • Genetic susceptibility to naevi--a twin study..  64:1164-1167. 1991
  • Flow cytometric analysis of cell surface carbohydrates in metastatic human breast cancer..  62:238-242. 1990
  • Double antibody radioimmunoassay for monitoring metastatic breast cancer..  58:362-367. 1988
  • B-Lymphocytes from melanoma patients and normal individuals react with melanoma cells but also with irrelevant antigens.  58:182-185. 1988
  • Influence of tumour size on human prostate tumour metastasis in athymic nude mice..  51:419-423. 1985
  • A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas..  51:283-289. 1985
  • C-type virus particles in human urogenital tumours after heterotransplantation into nude mice..  39:35-42. 1979
  • Inducers of Friend leukaemic cell differentiation in vitro--effects of in vivo administration..  33:634-645. 1976
  • Proceedings: Oral and pharyngeal cancers in textile workers..  32:249. 1975
  • Membrane receptor sites for the identification of lymphoreticular cells in benign and malignant conditions.  31:107-120. 1975
  • Refusal in testicular cancer patients: implications for surveillance..  65:786. 1992
  • A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. 2018
  • Enhancement of targeted radiotehrapy in neuroblastoma: A novel gene therapy approach 2004
  • Targeted radiotherapy of brain tumours 2003